Amphastar Q2 2023 revenue $145.7M, GAAP EPS $0.49, adj. EPS $0.65

Amphastar Pharmaceuticals, Inc.

2023-Q2 EPS reported $0.99 revenue$285,734,000

Net revenues $145.7M for Q2 2023, up 18% from $123.5M in Q2 2022.
GAAP net income $26.1M ($0.49 diluted EPS) vs $17.3M ($0.33) YoY.
Adjusted non-GAAP net income $34.8M ($0.65 diluted EPS) vs $20.7M ($0.39) YoY.
Completed BAQSIMI acquisition June 30; glucagon, phytonadione, and newer products drove growth.
Six-month: revenue $285.7M, GAAP net income $52.2M ($0.99 EPS), adj. net income $66.9M ($1.27 EPS).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.